Which has preferable valuation & earnings, IBRX or BIIB?

Biogen has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 94.67 -$351.40M -$0.97 N/A Biogen $9.89B 3.43 $1.29B $5.65 40.60

Is IBRX or BIIB more profitable?

Biogen has a net margin of 8.32% compared to ImmunityBio's net margin of -598.55%. Biogen's return on equity of 11.18% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Biogen 8.32% 11.18% 6.88%

Does the media prefer IBRX or BIIB?

In the previous week, Biogen had 18 more articles in the media than ImmunityBio. MarketBeat recorded 31 mentions for Biogen and 13 mentions for ImmunityBio. Biogen's average media sentiment score of 0.49 beat ImmunityBio's score of 0.45 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 10 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to IBRX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than ImmunityBio. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 13 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.45 beat Alnylam Pharmaceuticals' score of 0.30 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IBRX or ROIV?

In the previous week, ImmunityBio had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for ImmunityBio and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.67 beat ImmunityBio's score of 0.45 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IBRX or BNTX more profitable?

BioNTech has a net margin of -63.54% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% BioNTech -63.54% -6.86% -6.00%

Does the media favor IBRX or BNTX?

In the previous week, BioNTech had 15 more articles in the media than ImmunityBio. MarketBeat recorded 28 mentions for BioNTech and 13 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.45 beat BioNTech's score of 0.44 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 10 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to UTHR or IBRX?

In the previous week, United Therapeutics had 1 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for United Therapeutics and 13 mentions for ImmunityBio. United Therapeutics' average media sentiment score of 0.74 beat ImmunityBio's score of 0.45 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ImmunityBio (IBRX) Competitors

$9.80 -0.32 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$9.84 +0.04 (+0.41%)

As of 07:55 PM Eastern

Compare

IBRX vs. BIIB, ALNY, ROIV, BNTX, and UTHR

Should you buy ImmunityBio stock or one of its competitors? ImmunityBio's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), BioNTech (BNTX), and United Therapeutics (UTHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImmunityBio compare to Biogen?

ImmunityBio (NASDAQ:IBRX) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Biogen has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	94.67	-$351.40M	-$0.97	N/A
Biogen	$9.89B	3.43	$1.29B	$5.65	40.60

ImmunityBio has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, Biogen has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 40.32%. Biogen has a consensus target price of $236.04, suggesting a potential upside of 2.89%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts plainly believe ImmunityBio is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Biogen	1 Sell rating(s)	12 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.59

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to ImmunityBio's net margin of -598.55%. Biogen's return on equity of 11.18% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Biogen	8.32%	11.18%	6.88%

In the previous week, Biogen had 18 more articles in the media than ImmunityBio. MarketBeat recorded 31 mentions for Biogen and 13 mentions for ImmunityBio. Biogen's average media sentiment score of 0.49 beat ImmunityBio's score of 0.45 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	10 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Biogen beats ImmunityBio on 12 of the 16 factors compared between the two stocks.

How does ImmunityBio compare to Alnylam Pharmaceuticals?

ImmunityBio (NASDAQ:IBRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than ImmunityBio. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 13 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.45 beat Alnylam Pharmaceuticals' score of 0.30 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 40.32%. Alnylam Pharmaceuticals has a consensus price target of $366.65, indicating a potential upside of 61.51%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Alnylam Pharmaceuticals has a net margin of 15.26% compared to ImmunityBio's net margin of -598.55%. Alnylam Pharmaceuticals' return on equity of 84.93% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmunityBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	94.67	-$351.40M	-$0.97	N/A
Alnylam Pharmaceuticals	$3.71B	8.18	$313.75M	$5.38	42.20

Summary

Alnylam Pharmaceuticals beats ImmunityBio on 14 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Roivant Sciences?

ImmunityBio (NASDAQ:IBRX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Roivant Sciences has lower revenue, but higher earnings than ImmunityBio. Roivant Sciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	94.67	-$351.40M	-$0.97	N/A
Roivant Sciences	$7.53M	3,317.20	-$299.77M	-$0.53	N/A

In the previous week, ImmunityBio had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for ImmunityBio and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.67 beat ImmunityBio's score of 0.45 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

ImmunityBio has a net margin of -598.55% compared to Roivant Sciences' net margin of -3,534.96%. ImmunityBio's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 40.32%. Roivant Sciences has a consensus target price of $45.64, suggesting a potential upside of 31.94%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Roivant Sciences	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

ImmunityBio and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does ImmunityBio compare to BioNTech?

ImmunityBio (NASDAQ:IBRX) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

ImmunityBio currently has a consensus price target of $14.20, suggesting a potential upside of 40.32%. BioNTech has a consensus price target of $125.69, suggesting a potential upside of 31.14%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65

ImmunityBio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

ImmunityBio has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	94.67	-$351.40M	-$0.97	N/A
BioNTech	$3.25B	7.47	-$1.29B	-$7.83	N/A

BioNTech has a net margin of -63.54% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
BioNTech	-63.54%	-6.86%	-6.00%

In the previous week, BioNTech had 15 more articles in the media than ImmunityBio. MarketBeat recorded 28 mentions for BioNTech and 13 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.45 beat BioNTech's score of 0.44 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	10 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ImmunityBio beats BioNTech on 9 of the 16 factors compared between the two stocks.

How does ImmunityBio compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and ImmunityBio (NASDAQ:IBRX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

United Therapeutics presently has a consensus price target of $627.31, suggesting a potential upside of 14.04%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 40.32%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, United Therapeutics had 1 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for United Therapeutics and 13 mentions for ImmunityBio. United Therapeutics' average media sentiment score of 0.74 beat ImmunityBio's score of 0.45 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

United Therapeutics has a net margin of 41.56% compared to ImmunityBio's net margin of -598.55%. United Therapeutics' return on equity of 20.18% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
ImmunityBio	-598.55%	N/A	-51.65%

United Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.95	19.68
ImmunityBio	$113.29M	94.67	-$351.40M	-$0.97	N/A

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Summary

United Therapeutics beats ImmunityBio on 12 of the 17 factors compared between the two stocks.

Get ImmunityBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBRX vs. The Competition

Export

Metric	ImmunityBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.73B	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-10.10	9.68	192.82	18.95
Price / Sales	91.68	1,149.10	561.77	81.02
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-19.22	16.95	10.71	6.03
Net Income	-$351.40M	-$22.69M	$3.50B	$380.34M
7 Day Performance	1.14%	-4.83%	-3.18%	-3.04%
1 Month Performance	23.89%	-12.20%	-6.61%	-5.16%
1 Year Performance	295.16%	8.87%	3.69%	-2.48%

ImmunityBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBRX ImmunityBio	2.9838 of 5 stars	$9.80 -3.2%	$14.20 +44.9%	+328.8%	$10.73B	$113.29M	N/A	691
BIIB Biogen	2.7003 of 5 stars	$225.37 +1.1%	$230.14 +2.1%	+56.5%	$33.20B	$10.03B	39.77	7,500	Trending News Analyst Upgrade
ALNY Alnylam Pharmaceuticals	4.2027 of 5 stars	$226.20 +1.0%	$366.90 +62.2%	-50.6%	$30.22B	$4.80B	41.97	2,770
ROIV Roivant Sciences	2.7595 of 5 stars	$35.13 -1.1%	$45.64 +29.9%	+115.6%	$25.37B	$7.53M	N/A	721	Analyst Downgrade
BNTX BioNTech	3.908 of 5 stars	$96.55 +0.9%	$125.69 +30.2%	-6.1%	$24.41B	$3.25B	N/A	7,807	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBRX) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmunityBio (IBRX) Competitors

IBRX vs. BIIB, ALNY, ROIV, BNTX, and UTHR

How does ImmunityBio compare to Biogen?

Summary

How does ImmunityBio compare to Alnylam Pharmaceuticals?

Summary

How does ImmunityBio compare to Roivant Sciences?

Summary

How does ImmunityBio compare to BioNTech?

Summary

How does ImmunityBio compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmunityBio (IBRX) Competitors

IBRX vs. BIIB, ALNY, ROIV, BNTX, and UTHR

How does ImmunityBio compare to Biogen?

Which has preferable valuation & earnings, IBRX or BIIB?

Which has more risk & volatility, IBRX or BIIB?

Do analysts recommend IBRX or BIIB?

Do insiders and institutionals believe in IBRX or BIIB?

Is IBRX or BIIB more profitable?

Does the media prefer IBRX or BIIB?

Summary

How does ImmunityBio compare to Alnylam Pharmaceuticals?

Does the media refer more to IBRX or ALNY?

Do analysts prefer IBRX or ALNY?

Is IBRX or ALNY more profitable?

Do insiders and institutionals have more ownership in IBRX or ALNY?

Which has more risk and volatility, IBRX or ALNY?

Which has stronger earnings & valuation, IBRX or ALNY?

Summary

How does ImmunityBio compare to Roivant Sciences?

Do institutionals & insiders have more ownership in IBRX or ROIV?

Which has preferable earnings and valuation, IBRX or ROIV?

Does the media favor IBRX or ROIV?

Which has more volatility and risk, IBRX or ROIV?

Is IBRX or ROIV more profitable?

Do analysts prefer IBRX or ROIV?

Summary

How does ImmunityBio compare to BioNTech?

Do analysts rate IBRX or BNTX?

Which has more volatility and risk, IBRX or BNTX?

Which has preferable earnings & valuation, IBRX or BNTX?

Is IBRX or BNTX more profitable?

Does the media favor IBRX or BNTX?

Do insiders and institutionals hold more shares of IBRX or BNTX?

Summary

How does ImmunityBio compare to United Therapeutics?

Do analysts rate UTHR or IBRX?

Does the media refer more to UTHR or IBRX?

Do institutionals and insiders hold more shares of UTHR or IBRX?

Is UTHR or IBRX more profitable?

Which has better earnings & valuation, UTHR or IBRX?

Which has more volatility & risk, UTHR or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools